TRM-201 (rofecoxib) is an oral nonsteroidal anti-inflammatory drug (NSAID) being developed by Tremeau Pharmaceuticals to treat hemophilic arthropathy, a degenerative joint disease that can occur due to recurrent joint bleeds in people with hemophilia.
Search results for:
Hemophilia is a genetic disorder where the blood cannot clot properly due to a deficiency in clotting factors, leading to prolonged and heavy bleeding. There is currently no cure for hemophilia, but various treatment options exist. TRM-201 (rofecoxib) is an oral NSAID being developed to treat hemophilic arthropathy, a degenerative joint disease caused by recurrent joint bleeds in people with hemophilia.
AI-generated summaries are for informational use only, based on content from multiple pages. They may not reflect full context. For complete details, see the original sources. Consult a qualified healthcare professional for medical advice.
Funding has been set for the RESET-HA Phase 3 clinical trial evaluating Tremeau Pharmaceuticals‘ TRM-201 (rofecoxib) in people with hemophilic arthropathy — a painful and degenerative disease caused by recurrent bleeding in the joints. The private investment firm Gurnet Point Capital also will support other aspects of TRM-201‘s…
Hemophilia is a disorder wherein the blood is not able to clot properly. As a result, patients bleed easily, and it's unusually prolonged and heavy.
Hemophilia A is a rare genetic disorder that affects the blood’s ability to clot properly. It is the most common form of hemophilia, responsible for 80% of all cases.
Social Clips
The Most Commonly Asked Questions About Hemophilia
Hemophilia is it a genetic disorder where the body doesn’t produce clotting factor, which means blood can’t clot. This makes patients susceptible to both heavy external and internal bleeding, which if left untreated, can be life-threatening. Thanks to Hemophilia Village, we have the answers to some of the most commonly…
In the U.S., hemophilia A is estimated to affect one in every 5,000 male births, hemophilia B one in 25,000 male births, and hemophilia C one in every 100,000 people (males and females). Hemophilia A is thus four times more common than hemophilia B, and about 10 times more common than…
Hemophilia is a rare disorder in which a person’s blood is not able to clot properly, resulting in unusually easy and prolonged bleeding.
There are several types of hemophilia, a rare bleeding disorder wherein the blood fails to clot properly. Hemophilia A and B are the most common types, while hemophilia C is comparatively rare.
Hemophilia, a disorder characterized by excessive bleeding, is caused by the lack of activity of certain clotting factors, which are proteins that are needed to form blood clots.